HB and Alpha Tau Medical partner to bring the world’s first Alpha Radiation Brachytherapy to Japan

HekaBio K.K. partnered with Alpha Tau Medical LTD, an Israeli company, to establish Alpha Tau Medical K.K in Japan on January 31, 2018. The purpose of Alpha Tau Medical K.K. is to supply and distribute to the Japanese market a highly potent and conformal alpha radiation-based cancer treatment, the Alpha DaRT.

Alpha Tau Medical LTD (Tel Aviv, Israel) developed the world’s first brachytherapy using alpha radiation for the treatment of solid cancers, including pancreatic, prostate, head & neck and other cancers. The treatment, Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy), is under clinical research in the EU, Asia and the United States. Clinical trials currently conducted in Europe and Israel confirm the efficacy and safety of the treatment.

Alpha DaRT therapy is effective for all solid carcinomas tested, including hypoxic tumors. Radioactive Alpha DaRT seeds are directly inserted into the tumor, releasing alpha particles and causing immediate destruction of cancer cell DNA while sparing surrounding healthy tissue.

Development and Clinical trial planning is are progressing in Japan with major cancer centers.


About Alpha Tau Medical LTD

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumor cancers. The Alpha DaRT technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari in 2003 at Tel Aviv University.

Alpha Tau Medical’s mission is “to enable a cancer treatment that destroys tumors while sparing healthy tissue to save the lives of millions of patients around the world.” (Alpha Tau Medical, Mission Statement)


For more information, please visit http://www.alphataumedical.com/ (English Only)


About the Alpha DaRT treatment

The Alpha DaRT treatment has several important features:

• Highly potent and conformal

• Proven efficacy for all solid tumors tested

• Effective regardless of tumor oxygen level

• Short half-life – quick clinical outcome

• No known negative systemic effects

• Stimulates anti-tumor immune response

• Single-session treatment

• Enables combination with other therapies or reapplication

• Disposable applicators - does not require capital equipment or special shielding


About HekaBio K.K.

Office: Yashima Bldg. 3F, 2-7-14 Toranomon, Minato-ku, Tokyo 105-0001

Tel: +81 (3) 6205-7585 Fax: +81 (3) 6205-7586

Chief Executive Officer: Robert E. Claar

HekaBio focuses on cancer, autoimmune/ inflammatory and central nervous system disease. The management team has extensive experience and networks, both overseas and in Japan.

With a deep understanding and respect for Japanese medical needs and business practices, HekaBio continues to grow by developing its innovation pipeline with validated programs from overseas partners. HekaBio strives to eliminate the innovation gap between Japan and rest of the world with the swift launch of therapies meeting unmet medical needs in Japan.

With integrity and tenacity, HekaBio collaborates with healthcare and business partners to creatively address the unmet medical needs of patients who are fighting rare and intractable diseases.

最新記事

すべて表示

AlphaTau Medical LtdとHealthcare Capital Corp.が合併し、アルファ粒子線照射による固形腫瘍の治療に焦点を当てた10億ドル規模の上場企業を設立

ヘカバイオ株式会社のパートナー企業であるAlpha Tau Medical Ltd は7月9日(現地時間7月8日)に、Special Purpose Acquisition Company(特別買収目的会社)であるHealthcare Capital Corp.(Nasdaq:HCCC)と共に上場企業を設立し、2021年末にかけてNasdaqへ上場すると発表しました。 両社によるプレスリリースはこ

ポリープ状脈絡膜血管症(加齢黄斑変性症の一種)の先進的治療を開発するSalutarisMD社とライセンス契約を締結

ヘカバイオ株式会社(以下、ヘカバイオ)は、加齢黄斑変性症の中でもアジア人に多いポリープ状脈絡膜血管症(PCV)の治療のため開発されたBetaCurveの日本におけるライセンスおよび商業化の契約をSalutaris Medical Devices Inc.(以下SalutarisMD社)と締結しました。 同社が開発したBetaCurveは、Sr90(ストロンチウム90:放射性同位元素)を用いたβ線を

新株発行により4億円の資金調達を達成

ヘカバイオ株式会社(東京都中央区日本橋本石町3-3-16)は2021年1月29日付にて4億円の第三者割当増資を行いました。 今回の増資により調達した資金は、今後当社が開発を手掛けるポートフォリオを拡充させるために活用いたします。 当社は、人々の医療と健康への貢献を使命として、世界への窓口として日本にベースに置き、海外の製品の導入に特化して開発や市場化を行っています。がん、線維性疾患、自己免疫性炎症